Alcon takes a new look at ophthalmic pharma space and marketing, post Novartis spinout and raft of acquisitions
When Alcon eye care spun out of Novartis as an independent company, the ophthalmology pharmaceuticals business stayed at the Big Pharma. For Alcon, though, it was an “obvious” gap in its eye care and eye health expertise, so it went out and began acquiring and building out a prescription eye drug portfolio.
Now four years after a handful of acquisitions — including a $770 million deal last August for Aerie Pharmaceuticals with two eye prescription meds plus a late-stage dry eye disease candidate — Alcon is stepping out with new marketing around its growing pharma portfolio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.